OSUR vs QDEL
OSUR: OrasuRe is a diagnostic company specializing in rapid point-of-care and self-test solutions for infectious diseases and rare conditions, with recent expansion into sickle cell screening through the BioMedomics acquisition. QDEL: Global diagnostics company providing immunoassay, molecular testing, clinical chemistry, and transfusion medicine solutions across labs, point-of-care, and molecular platforms.
Side-by-side fundamentals
| Metric | OSUR | QDEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.79 | $16.68 | |
| Market cap as of 2026-07-23 | $262M | $1.1B | |
| PEG as of 2026-07-23 | -0.03 | -0.00 | OSUR lower |
| Net margin as of 2026-07-23 | -66.4% | -45.6% | QDEL higher |
| Gross margin as of 2026-07-23 | +42.5% | +45.0% | QDEL higher |
| Operating margin as of 2026-07-23 | -68.6% | -37.2% | QDEL higher |
| ROE as of 2026-07-23 | -21.5% | -56.3% | OSUR higher |
| ROA as of 2026-07-23 | -18.2% | -20.6% | OSUR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.45 | OSUR lower |
| Revenue growth (YoY) as of 2026-07-23 | -30.1% | -3.9% | QDEL higher |
| Revenue CAGR (3y) SEC XBRL | -33.3% | +17.1% | QDEL higher |
| Beta as of 2026-07-23 | 1.03 | 0.69 | |
| 1-year return as of 2026-07-22 close | +9.9% | -34.7% | OSUR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.